EpiCept GmbH - rizultati

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

levetiracetam stada mixtúra, lausn 100 mg/ml

stada arzneimittel ag - levetiracetamum inn - mixtúra, lausn - 100 mg/ml

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalízúmab - margvísleg sclerosis - valdar ónæmisbælandi lyf - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax filmuhúðuð tafla 100 mg

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 100 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax filmuhúðuð tafla 200 mg

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 200 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax filmuhúðuð tafla 25 mg

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 25 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax filmuhúðuð tafla 50 mg

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 50 mg